Fidaxomicin: A guide to its use in Clostridium difficile infection

被引：0
作者：
Scott L.J. [1 ]
机构：
[1] 0754 Auckland, Adis 41 Centorian Drive, Private Bag 65901, Mairangi Bay
来源：
Drugs & Therapy Perspectives | 2014年 / 30卷 / 3期
关键词：
Vancomycin; Clinical Cure Rate; Fidaxomicin; Vancomycin Treatment; Vancomycin Group;
D O I：
10.1007/s40267-013-0105-1
中图分类号：
学科分类号：
摘要：
Fidaxomicin (Dificlir® [EU]; Dificid® [USA]) is a narrow-spectrum, first-in-class macrocyclic antibacterial that primarily shows activity against Clostridia spp., acts locally in the gastrointestinal tract and shows minimal or no activity against normal intestinal microflora. It is an effective and generally well tolerated option in the treatment of C. difficile infection. In clinical trials, fidaxomicin treatment was noninferior to vancomycin treatment with regard to clinical cure rates and was associated with significantly lower C. difficile infection recurrence rates and significantly higher global cure rates. © 2013 Springer International Publishing Switzerland.
引用
收藏
页码：85 / 91
页数：6
相关论文
共 31 条
  • [1] Johnson A.P., Wilcox M.H., Fidaxomicin: A new option for the treatment of Clostridium difficile infection, J Antimicrob Chemother., 67, 12, pp. 2788-2792, (2012)
  • [2] Cohen S.H., Gerding D.N., Johnson S., Et al., Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA), Infect Control Hosp Epidemiol., 31, 5, pp. 431-455, (2010)
  • [3] Cecil J.A., Clostridium difficile: Changing epidemiology, treatment and infection prevention measures, Curr Infect Dis Rep., 14, pp. 612-619, (2012)
  • [4] Drekonja D.M., Butler M., Macdonald R., Et al., Comparative effectiveness of Clostridium difficile treatments: A systematic review, Ann Intern Med., 155, 12, pp. 839-847, (2011)
  • [5] O'Horo J.C., Jindai K., Kunzer B., Et al., Treatment of recurrent Clostridium difficile infection: A systematic review, Infection, (2013)
  • [6] Khanna S., Pardi D.S., Clostridium difficile infection: New insights into management, Mayo Clin Proc., 87, 11, pp. 1106-1117, (2012)
  • [7] Cornely O.A., Current and emerging management options for Clostridium difficile infection: What is the role of fidaxomicin?, Clin Microbiol Infect., 18, SUPPL. 6, pp. 28-35, (2012)
  • [8] Sears P., Ichikawa Y., Ruiz N., Et al., Advances in the treatment of Clostridium difficile infection with fidaxomicin: A narrow spectrum antibiotic, Ann NY Acad Sci., 1291, 1, pp. 33-41, (2013)
  • [9] ) 200 Mg Film-coated Tablets: EU Summary of Product Characteristics, (2013)
  • [10] Scott L.J., Fidaxomicin: A review of its use in patients with Clostridium difficile infection, Drugs., 73, 15, pp. 1733-1747, (2013)
1234